SOURCE: QuantRx Biomedical Corporation

March 19, 2015 08:00 ET

QuantRx® Biomedical Provides Update on Point of Care Diagnostics Division

Uniquely Positioned to Capitalize on Multiple Large Market Opportunities With Its Advanced Lateral Flow Technologies; Actively Seeking Strategic Partners

PORTLAND, OR--(Marketwired - Mar 19, 2015) - QuantRx® Biomedical Corporation (OTCBB: QTXB) is pleased to announce that it is actively seeking strategic partners for its Point of Care ("POC") diagnostics division, which is focused on the commercialization of innovative lateral flow diagnostic products that utilize the Company's patented exceptionally sensitive and quantitative fluorescent lateral flow technology platforms.

The Company previously separated its assets and intellectual property into two wholly-owned operating divisions focused on 1) retail applications of its treated and untreated miniform pads including its InSync line of feminine care products and diagnostic applications utilizing its proprietary PadKit technology that enables the routine collection of biologic material for later analysis, testing and diagnosis in a laboratory setting; and 2) its rapid hyper-sensitive quantitative point of care fluorescent lateral flow technology platform. The Company has demonstrated clinical "proof of concept" for the POC system, with 10-minute tests for thyroid markers TSH and Free T4, previously only available as a laboratory based test.

Dr. Shalom Hirschman, Chairman of the Board at QuantRx Biomedical, stated, "The Company's broadly patented POC technology and products offer superior and innovative solutions to meet the need for rapid quantified results at the point of patient medical care. We are seeking strategic partnership opportunities to provide the necessary resources, personnel and capital necessary to drive success. Our ground breaking lateral flow diagnostics technologies, that allow sensitivity to 10 pico-grams per milliliter (or 1 specific grain of sand in 1,000 liters of sand), have the potential to define new standards of care and dramatically improve patient outcomes across a broad range diagnostic needs. It is a truly an exciting time in the history of the Company."

About QuantRx Biomedical, Inc.  
QuantRx Biomedical Corporation (OTCBB: QTXB) is focused on the development and commercialization of genomic products for advanced diagnosis of serious disease and health conditions, and innovative over-the-counter miniform based products (uniqueminiform.com). With synergistic expertise in the discovery of diagnostic platforms leveraging a significant portfolio of intellectual property, QuantRx's mission is to introduce products for use by its medical laboratory, and consumers that deliver more accurate, reliable, and cost-effective diagnoses which result in improved patient care and a reduction in overall healthcare costs.

The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company's technology portfolio, with more than a dozen patents, patents pending and licensed patents, includes: miniform technology for over-the-counter applications, and the diagnosis and treatment of women's health concerns and other medical needs, and significant opportunities in genomic screening and testing for adult and fetal applications, all of which are designed to address significant unmet medical needs by providing clinicians with important tools for early discovery and assessment.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, management's current plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including; general economic conditions, the Company's need for additional funds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. For a discussion of such risks and uncertainties, see "Risk Factors" in the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its other reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

Contact Information